AAS
ADMA icon

Ameritas Advisory Services’s ADMA Biologics ADMA Stock Holding History

Ameritas Advisory Services’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9 Buy
+1
New +$16 ﹤0.01% 1074
2025
Q4 		– Sell
-2,500
Closed -$36.6K – 938
2025
Q3 		$36.6K Hold
2,500
– – ﹤0.01% 1204
2025
Q2 		$45.5K Buy
+2,500
New +$51K ﹤0.01% 1354

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Ameritas Advisory Services's ADMA Position: Q1 2026 in Review

Ameritas Advisory Services opened a new position in ADMA Biologics (ADMA) in Q1 2026: 1 share worth $9. The stake represents ﹤0.01% of the portfolio and ranks #1074 among its holdings. This is a return to the name: Ameritas Advisory Services previously reported a position in ADMA as recently as Q3 2025.

Ameritas Advisory Services first reported a position in ADMA in Q2 2025 and has held it in 3 quarters since. The position peaked at $45.5K in Q2 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Ameritas Advisory Services held 1 share of ADMA Biologics worth $9 as of Q1 2026.
  • ADMA Biologics was a new Ameritas Advisory Services position in Q1 2026.
  • ADMA Biologics made up ﹤0.01% of Ameritas Advisory Services's portfolio in Q1 2026, its #1074 holding.
  • Ameritas Advisory Services first reported a position in ADMA Biologics in Q2 2025 and has held it in 3 quarters since.
  • Ameritas Advisory Services's ADMA Biologics position peaked at $45.5K in Q2 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Ameritas Advisory Services's 13F filing for Q1 2026, filed 12 May 2026.